timothy sykes logo
APUS Stock Rockets On Heavy Volume As Traders Hunt Volatility Thumbnail
G Google News

APUS Stock Rockets On Heavy Volume As Traders Hunt Volatility

ELLIS HOBBS•UPDATED SEP. 24, 2026, 9:19 AM ET
Reviewed by Matt Monacoand Fact-checked by Bryce Tuohey

Apimeds Pharmaceuticals US Inc. soared as breakthrough drug trial success fueled bullish sentiment; stocks have been trading up by 163.81 percent.

Key Takeaways

  • APUS has bounced sharply off recent lows, with intraday action spiking from the low $2s into the $6s on aggressive volume and wide trading ranges.
  • The company behind APUS, Apimeds Pharmaceuticals US Inc., shows deep losses but also a large asset base and low debt, creating a classic high-risk, high-volatility profile.
  • APUS trades at a tiny fraction of its book value, drawing in value-focused and momentum traders looking for mispriced biopharma names.
  • Weak liquidity and negative cash flow mean Apimeds Pharmaceuticals US Inc. remains a pure trading vehicle, not a long-term safety play.
  • Short-term traders are watching whether APUS holds key support levels after this sharp intraday squeeze.

Candlestick Chart

Live Update At 09:18:40 EDT: On Thursday, September 24, 2026 Apimeds Pharmaceuticals US Inc. stock [NYSE American: APUS] is trending up by 163.81%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

APUS is trading like a rollercoaster, and the financials explain why. Apimeds Pharmaceuticals US Inc. carries total assets of about $127.6M against total liabilities of roughly $21.2M, leaving common equity near $106.4M. Yet the market is valuing APUS at a fraction of that, with a price-to-book ratio around 0.03. That’s classic deep-discount territory that often attracts speculative trading.

The income statement is ugly. APUS shows net income of about -$20.2M for the recent quarter, with a basic EPS of -$11.77. Return on equity is heavily negative, and return on assets is deeply in the red. For traders, that means Apimeds Pharmaceuticals US Inc. is burning cash, not generating it.

More Breaking News

The cash flow picture backs this up. APUS posted operating cash flow of about -$5.7M and free cash flow around -$5.7M as well. The current ratio sits near 0.5, signaling tight near-term liquidity. There is current debt of about $14.4M against a relatively small unrestricted cash balance. In simple terms, APUS is fundamentally weak but structurally cheap, which is exactly the combo that fuels volatile trading setups.

Why Traders Are Watching APUS Price Action

APUS has become a textbook momentum playground. On the daily chart, Apimeds Pharmaceuticals US Inc. slid from around $4.09 on 2026/08/31 down to closes in the mid-$1s and low $2s by late September. That’s a steep downtrend, but it also set the stage for sharp bounces. From a close near $1.64–$1.77 range, APUS snapped back to $2.29, showing the first signs of buyers stepping in around prior lows.

The intraday 5‑minute chart is where things get wild. APUS opened the premarket near $2.25–$2.38 and then exploded. Price ripped from the low $2s to above $3, then $4, then tagged the high $6s, with a peak near $6.98 before fading back toward the low $6s. For Apimeds Pharmaceuticals US Inc., that is a multi-bagger intraday move, the kind of squeeze that momentum traders live for.

This type of expansion from $2 to nearly $7 tells traders a few things. First, APUS has a thin float or at least highly reactive supply-demand dynamics, so any surge in buying can send it vertical. Second, Apimeds Pharmaceuticals US Inc. is clearly on the radar of day traders who chase halts, VWAP holds, and breakout levels. Third, that huge range also warns that late chasers risk being trapped if APUS gives back gains just as fast.

Technically, traders will watch whether APUS can build a base above former resistance zones around $3–$4. If Apimeds Pharmaceuticals US Inc. keeps holding higher lows after this squeeze, it may set up more secondary runs. If not, it becomes another one-and-done spike on the chart that rewards early entries and punishes hesitation.

Conclusion

APUS sits in that dangerous but attractive zone where fundamentals look terrible, yet the chart screams opportunity. Apimeds Pharmaceuticals US Inc. is losing money, burning cash, and running with a tight current ratio and negative returns. On paper, that would scare away conservative capital. For active traders, though, the huge gap between book value and market price, plus the violent intraday swings, is exactly what creates edge.

The key is discipline. APUS will not reward hope; it rewards planning. As millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.”. Traders focusing on Apimeds Pharmaceuticals US Inc. should treat it as a short-term trading vehicle, studying support, resistance, and volume profiles intraday. Risk management has to come first, especially when a name can move from $2 to nearly $7 in under an hour.

Tim Sykes always hammers the same rule: “Cut losses quickly. That’s the key to long-term trading success.” APUS demands that mindset. Respect the volatility, size down, and let the chart, not emotion, drive decisions. For now, Apimeds Pharmaceuticals US Inc. is a high-volatility education in how fast a beaten-down ticker can come back to life — and how quickly it can turn on anyone who gets sloppy. This analysis is for educational and research purposes only, and every trader must do their own homework before acting.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”